BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 17982490)

  • 1. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
    Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathological features of breast cancer in carriers of ATM gene variants.
    Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
    Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role for ATM in DNA damage-induced phosphorylation of BRCA1.
    Gatei M; Scott SP; Filippovitch I; Soronika N; Lavin MF; Weber B; Khanna KK
    Cancer Res; 2000 Jun; 60(12):3299-304. PubMed ID: 10866324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What do we know about ATM protein expression in breast tissue?].
    Angèle S; Tanière P; Hall J
    Bull Cancer; 2001 Jul; 88(7):671-5. PubMed ID: 11495820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
    Santarosa M; Maestro R
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):131-42. PubMed ID: 22101651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 protein expression and its correlation with ER/PR status in sporadic and familial breast cancer in Eastern Indian patients--a hospital based study.
    Ashraf M; Jha JK; Mukherjee N; Panda CK; Nayak S; Jadhav TS; Dikshit N; Nath NC; Chakraborty J; Biswas J
    J Indian Med Assoc; 2011 Dec; 109(12):873-8. PubMed ID: 23469566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.
    Zakhartseva LM; Gorovenko NG; Podolskaya SV; Anikusko NF; Lobanova OE; Pekur KA; Kropelnytskyi VA; Shurygina OV
    Exp Oncol; 2009 Sep; 31(3):174-8. PubMed ID: 19877382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
    Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J
    Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining.
    Wang HC; Chou WC; Shieh SY; Shen CY
    Cancer Res; 2006 Feb; 66(3):1391-400. PubMed ID: 16452194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor suppressor genes and breast cancer.
    Buchholz TA; Weil MM; Story MD; Strom EA; Brock WA; McNeese MD
    Radiat Oncol Investig; 1999; 7(2):55-65. PubMed ID: 10333246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways.
    Keimling M; Volcic M; Csernok A; Wieland B; Dörk T; Wiesmüller L
    FASEB J; 2011 Nov; 25(11):3849-60. PubMed ID: 21778326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.
    Pristauz G; Petru E; Stacher E; Geigl JB; Schwarzbraun T; Tsybrovskyy O; Winter R; Moinfar F
    Histopathology; 2010 Dec; 57(6):877-84. PubMed ID: 21166701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
    Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
    Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
    Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
    Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.
    Brunet J; Gutiérrez-Enríquez S; Torres A; Bérez V; Sanjosé S; Galceran J; Izquierdo A; Menéndez JA; Gumà J; Borràs J
    Clin Genet; 2008 May; 73(5):465-73. PubMed ID: 18384426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
    Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
    Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.